Sanofi Offers Rs 117 Final Dividend: Will It Trigger Bullish Momentum Before 25th April?

Sanofi India is a multinational biopharmaceutical business that prioritizes human wellness. The organization has four global business groups and significant healthcare fields, and it is present in 100 countries and offers healthcare solutions in more than 170 nations worldwide. With over 100,000 employees from 145 different countries, it is one of the most respected corporations in the world. Additionally, it is among the few Indian healthcare organizations with a well-established, extensive industrial footprint. Following the Board's announcement of the record date for an enormous final dividend of Rs 117/-per equity share for the financial year ending December 31, 2024, Sanofi India's shares finished Wednesday's trading session on the NSE 0.41% down at Rs 5,600 with a market capitalization of Rs 12.90KCr.

Sanofi India Dividend

"We refer to our intimation dated 27th February 2025, informing that the Board, at its meeting held on 27th February 2025, had recommended a final dividend of Rs 117/- per equity share of the face value of Rs 10 each for the Financial Year ended 31st December 2024, subject to the approval of Shareholders at the ensuing 69th Annual General Meeting. In the above context, payment of the Final Dividend will be made to those members whose names are on the Company's Register of Members on Friday, 25th April 2025 ("Record Date") and those whose names appear as Beneficial Owners as at the close of the business hours on Friday, 25th April 2025 as per the details to be furnished by the Depositories, viz. NSDL and CDSL, for this purpose," said Sanofi India in a stock exchange filing on Tuesday.

Sanofi India News

"The Board, based on the recommendation of the Nomination and Remuneration Committee, have approved the re-appointment of Mr. Rahul Bhatnagar (DIN: 07268064) as an Independent Director of the Company for a second term of five consecutive years starting from 29th July 2025 to 28th July 2030. The current term of Mr. Rahul Bhatnagar as an Independent Director of the Company is set to conclude on 28th July 2025. The said reappointment is subject to the approval of the Members through special resolution at the ensuing 69th Annual General Meeting of the Company. Mr. Rahul Bhatnagar has submitted a declaration that he meets the criteria for independence as provided under Section 149(6) of the Act and Regulation 16(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. He has also confirmed that he has not been debarred from holding the office of Director by virtue of any Order passed by the Securities and Exchange Board of India or any other such authority," informed Sanofi India to stock exchanges on 18th March.

Sanofi India Share Price Target

Mandar Bhojane - Equity Research Analyst at Choice Broking said, "SANOFI is currently trading at 5,605.10 and is showing signs of recovery after a prolonged downtrend. The stock has been forming a base at lower levels and has recently gained upward momentum, indicating a potential trend reversal or relief rally. It has successfully crossed above short-term moving averages, suggesting growing strength. However, the 200-day EMA remains a critical resistance level that the stock has yet to surpass. Additionally, the stock has found strong support at its 50-day EMA, reinforcing the current upward movement."

"On the upside, resistance is observed in the 5,750-5,800 range. A breakout above this level could propel the stock toward a short-term target of 6,000. Conversely, immediate support is positioned at 5,500, with a suggested stop-loss at 5,400 to mitigate downside risk. The Relative Strength Index (RSI) is currently at 60.78 and trending upward, indicating strengthening buying momentum and further upside potential," the analyst added.

"In conclusion, SANOFI presents a promising buying opportunity, with an upside potential toward 6,000 based on technical analysis and prevailing market conditions. However, traders should implement proper risk management strategies to protect against potential market reversals," Mandar Bhojane recommended.

Disclaimer

The recommendations made above are by market analysts and are not advised by either the author, nor Greynium Information Technologies. The author, nor the brokerage firm nor Greynium would be liable for any losses caused as a result of decisions based on this write-up. Goodreturns.in advises users to consult with certified experts before making any investment decision.